EUCTR2004-002757-31-SE进行中（未招募）1 期
A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy
ovartis Sverige AB0 个研究点目标入组 0 人开始时间: 2004年10月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Details of inclusion and exclusion into the core study can be found in the core protocol.
- •Inclusion criteria for Extension
- •1. Written informed consent to participate in the extension study.
- •2. Ability to comply with all study requirements.
- •3. Agreement to maintain the same dose of metformin as in the core study in the extension study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Premature discontinuation from the core study.
- •2. Concomitant medical conditions that interfere with the interpretation of study results as defined in the original protocol.
- •3. Failure to comply with the original study protocol.
- •4. Any patients that the primary investigator decides should not participate in the extension study.
研究者
相似试验
进行中（未招募）
不适用
An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment.Donezepil HCl for treatment of patients with CADASIL (Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy) who have cognitive impairment.MedDRA version: 6.1Level: PTClassification code 10009843EUCTR2004-001162-40-ITEISAI LTD UK
进行中（未招募）
1 期
28 Week Phase 3 study and 24 Week extension followed by a 52-week extension to evaluate efficacy and safety of Exenatide once weekly and Dapagliflozin versus Exenatide and Dapagliflozin matching placeboMedDRA version: 19.0Level: HLTClassification code 10012602Term: Diabetes mellitus (incl subtypes)System Organ Class: 100000004860Diabetes MellitusEUCTR2014-003503-29-HUAstraZeneca AB660
进行中（未招募）
1 期
28 Week Phase 3 study and 24 Week extension followed by a 52 Week extension to evaluate efficacy and safety of Exenatide once weekly and Dapagliflozin versus Exenatide and Dapagliflozin matching placeboDiabetes MellitusEUCTR2014-003503-29-SKAstraZeneca AB660
进行中（未招募）
不适用
A 28-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetesExtensión de 28 semanas del estudio multicéntrico, aleatorizado, doble ciego, con control activo que compara el efecto de 24 semanas de tratamiento con 50 mg bid de LAF237 frente a 8 mg qd de rosiglitazona en pacientes naive con diabetes Tipo 2.Diabetes Mellitus IIEUCTR2004-002644-10-ESovartis Farmaceutica S.A.660
进行中（未招募）
不适用
A 24-weeks , national, multicenter, double blind controlled vs placebo trial to evaluate the efficacy of Neoral ciclosporine 5mg/kg/day , twice a week administered in reduction of the rate of relapse in pz with chronic plaque psoriasis on remission. PREWENT Study - PREWENT StudyChronic plaque psoriasis on remissionMedDRA version: 6.1Level: PTClassification code 10037153EUCTR2006-000207-42-ITOVARTIS FARMA264